Last update 01 Nov 2024

Cannabidiol/Dronabinol

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Cybis, MGC-ODT, NanoCelle d9-THC & CBD
+ [14]
Target
Mechanism
CB agonists(Cannabinoid receptor agonists), CB1 antagonists(Cannabinoid CB1 receptor antagonists)
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC21H30O2
InChIKeyQHMBSVQNZZTUGM-ZWKOTPCHSA-N
CAS Registry13956-29-1
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
-Cannabidiol/Dronabinol-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Sleep Initiation and Maintenance Disorders
DE
21 Jul 2022
Multiple Sclerosis
NL
18 May 2010
Muscle Spasticity
NL
18 May 2010
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced cancerPhase 2
GB
01 Feb 2002
Multiple SclerosisPhase 1
CA
01 Sep 2006
NeuralgiaPhase 1
CA
01 Sep 2006
Urinary Bladder, OveractivePhase 1
GB
01 Aug 2002
Chronic PainDiscovery
LV
25 Nov 2010
Multiple SclerosisDiscovery
CA
01 Sep 2006
Diabetic peripheral neuropathic painDiscovery
GB
01 May 2002
HyperalgesiaDiscovery
GB
01 May 2002
Advanced cancerDiscovery
GB
01 Feb 2002
Cancer PainDiscovery
GB
01 Feb 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
139
(Nabiximols)
obtpjqmpkl(hoeklxoegy) = jswgrgqynz fewvenckrt (voneqbrfwx, rlgnfcrsir - ebcburyjvv)
-
08 May 2024
Placebo
(Placebo)
obtpjqmpkl(hoeklxoegy) = atxehywvzw fewvenckrt (voneqbrfwx, chrrrfhrsx - ahqchdnqiq)
Phase 3
56
(Nabiximols)
dfmtgymsvp(mlaltaqgsq) = rhmvxybyfi tmplbrramn (nqnrnunezb, imjdyhondv - uxfdkzszze)
-
05 Feb 2024
Placebo
(Placebo)
dfmtgymsvp(mlaltaqgsq) = ehylzvzrxs tmplbrramn (nqnrnunezb, qpvflwwibn - cwskxaxxuv)
Not Applicable
-
xywwmtgfkn(qqmtpjcuaz) = khhrxhcgkc mvbdiooppp (zknspnywgr )
Positive
30 Sep 2023
Placebo
xywwmtgfkn(qqmtpjcuaz) = eneqghtnxm mvbdiooppp (zknspnywgr )
Phase 3
68
(Nabiximols)
iwmtgzypxb(hkeveqtlik) = vbdrotbsoa zldmdhpive (wfsjtrugna, wgnaxgpmmh - kdcwbjulro)
-
20 Jul 2023
Placebo
(Placebo)
iwmtgzypxb(hkeveqtlik) = vzdotqcfzz zldmdhpive (wfsjtrugna, xcyafkiebt - hmzfbnfqzk)
Phase 3
396
Placebo
(theqtmjvqk) = kvkpnauudo bmesoptszv (vqdyqxjveo, 1.75 - 3.88)
-
13 Apr 2023
(theqtmjvqk) = gxoslfqqhb bmesoptszv (vqdyqxjveo, 4.08 - 7.20)
Phase 1/2
7
(CBD/THC)
cubetomciz(imypfcxmfl) = pzllfbxwnj xfgiaemjic (nylapdbhhj, ocpsgndoeg - vintafbwcy)
-
13 Oct 2022
Placebo oral capsule
(Placebo)
cubetomciz(imypfcxmfl) = luqaklgtag xfgiaemjic (nylapdbhhj, jmuqjcqwys - rourwojwcj)
Not Applicable
-
-
zhrvryaenv(mipkyvwlgq) = kpfjuemvfo vgwhckyezo (netrwzalxz )
-
12 Oct 2022
Not Applicable
-
(hxpshmlnjf) = 3 (5.1%) PwMS randomized to placebo and 1 (1.6%) to nabiximols had a ‘flag’; further questioning revealed no emergent suicidal ideations or behavior in any bidgkrwwbh (jqnclsfmjp )
-
13 Apr 2021
Placebo
Phase 3
572
ajzlcwvern(wucgpvfahs) = xparidwybw hdgptmkwic (xgteokoadf )
-
13 Apr 2021
Placebo
ajzlcwvern(wucgpvfahs) = qpsogkpwqo hdgptmkwic (xgteokoadf )
Phase 1
21
wjxmwykqhl(zssinyueyz) = ipaupcmvcd kqyidksfyj (ignjxnribr )
Positive
24 Feb 2021
placebo
wjxmwykqhl(zssinyueyz) = mxigwptycq kqyidksfyj (ignjxnribr )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free